You just read:

Algeta Announces Radium-223 Chloride Met its Primary Endpoint of Significantly Improving Overall Survival in a Phase III Trial in Patients With Castration-Resistant Prostate Cancer That Has Spread to the Bone

News provided by

Algeta

06 Jun, 2011, 08:50 BST